Abstract Objectives
Introduction
Polymyalgia rheumatica (PMR) is a syndrome characterized by proximal muscular pain and stiffness (1) . Its prevalence is 0.37% (95% CI 0.29-0.44) in the Italian general population aged 18 years and older (2) . PMR affects elderly people and is often associated with systemic manifestations and elevated concentrations of acute-phase reactants. Therapy relies on oral steroids, with prednisone at initial doses of 15 mg daily with progressive tapering usually suppressing infl ammation dramatically (3) . However, up to 60% of patients experience exacerbations during steroid tapering, and several studies suggest that only rarely steroid treatment can be discontinued before two years (3) . Long-term treatment with steroids is often complicated by side effects, particularly osteoporosis, hypertension, hyperglycemia, and cataract (4) . As a result, new therapeutic options are been investigated, especially for the benefi t of patients at high risk for steroid-related toxicity. The options that have been considered include different ways of administration of steroids, such as intramuscular (5) or intraarticular metilprednisolone (6), or steroid boli (7) , and several disease modifying treatments to be associated with steroids. We have recently demonstrated that combination therapy with prednisone and methotrexate (MTX) is effective as steroid-sparing treatment for patients with newly diagnosed PMR (8) . This schedule reduces the incidence of fl are-ups and the amount of prednisone required to maintain remission. However, at short-term follow-up no substantial reduction was found in the incidence of steroid-related side effects in MTX-treated patients despite the lower cumulative dose of prednisone they received. We postulated that, besides the reduced observation period, other possible explanations for this lack of side effect improvement could be the narrow difference in the cumulative dose of prednisone between groups, and the low incidence of side effects in this relatively "healthy" group of PMR patients, a common problem of controlled trials. To test the short-term follow-up hypothesis, we reviewed the charts of the participating patients and visited them again at fi ve years on average after completion of the original study. Besides assessing the incidence of long-term side effects of the combined treatement for PMR, additional end-points of this study included evaluation of the number of patients still in need of steroid treatment, the cumulative steroid dose administered, and the number of recurrences and relapses of PMR. The long-term follow-up permitted to evaluate the natural history of treated PMR and the alternative reasons for articular pain and persisting steroid administration.
Patients and methods
As previously described (8) , 72 PMR patients were enrolled by fi ve Italian rheumatology clinics in a multicentric randomised, double-blind, placebocontrolled trial on the effi cacy of oral MTX (10 mg weekly) in addition to 25 mg/day prednisone, with the steroid being tapered progressively and discontinued within 24 weeks. Steroid treatement was increased in dosage or restored in case of fl are-ups. End points included the proportion of patients who discontinued prednisone treatment, number of fl are-ups, and cumulative prednisone dose after 76 weeks. Four of the original fi ve rheumatologic tertiary referral centers participating in the controlled trial, which covered 61 of the original 72 (84.7%) patients, agreed to participate in the subsequent study. Patients were contacted by phone and asked to visit the clinic. Their history was recorded and they were visited following a standardized protocol. Patients' GPs were asked for previous and ongoing diseases and clinical charts were reviewed, when deemed necessary. If the patient was dead or unavailable for clinical examination, a close relative was interviewed. Information was collected on the patient's previous health and cause of death through a standardized structured questionnaire. The information required included demographic data, duration and dosage of steroid treatment, number of fl are-ups, a 100 mm visual analogue scale of pain and physician's evaluation, clinical fi ndings, laboratory examinations, the health assessment questionnaire (HAQ), and a list of possible adverse events. CRP and ESR were performed on all patients seen in the clinic and results of recent examinations were asked to those contacted by phone. We defi ned a fl are-up of signs and symptoms of PMR (aching and stiffness at shoulder, hip girdle or both) accompanied by an increased ESR (>30 mm/h), CRP concentration (>5 mg/L), or both as a relapse if it was observed during steroid tapering and as a recurrence, if it was observed after steroid withdrawal. However due to the retrospective design of this study, patients could not always remember if fl are-ups occurred with or without therapy. As a result, relapses and recurrences were considered together. The clinical referral forms of the original study were retrieved to allow correlation between long-term outcome data and clinical and laboratory information at enrolment. The ethics committees of the participating centres approved the protocol of the original study (8) . The informed consent explained to and signed by the patients included the authorization to contact them even after formal completion of the study in order to assess their health conditions. Statistics included comparison of means by Wilcoxon rank sum test and of percentages by Pearson's chi square test and by Fisher's exact test. Association between variables was tested by Spearman's rank correlation. A logistic regression procedure was used to evaluate variables infl uencing the main outcomes. A two-sided p-value less than 0.05 indicated statistical signifi cance. We used Medcalc software (Belgium), version 8.1.1.0 for all analyses.
Results
Data were obtained from 57/61 (93.4%) of the patients after a mean interval of 58.8±11.1 months after completion of the original study. Forty-two (73.7%) agreed to visit the clinic and underwent clinical examination, fi ve (8.8%) refused to come to the clinic and were interviewed by phone, and 10 (17.5%) were lost to follow-up. For this last cohort, a close relative (7 children, 2 spouses and 1 grandson) was interviewed. Twentynine patients (50.9%) belonged to the MTX-treated group and 28 (49.1%) to the placebo-treated group. The two groups were comparable for mean age, sex ratio, and duration of follow-up (Table I) . Five patients (10.6%) had died because of congestive heart failure (2 patients), cerebrovascular accident, myocardial infarction, or unknown cause. Two of the 29 MTX-treated patients (6.9%) were dead in comparison with 3/29 (10.3%) for controls. The differences in the clinical and laboratory features are reported in Table II . Potential side effects of steroid treatment were relatively rare. During follow-up, 58 side effects were observed Fourteen patients (24.6%) were assuming non-steroidal anti-infl ammatory drugs and 3 (5.3%) pure analgesics. They were equally distributed in the two subgroups.
Discussion
This is one of the few long-term studies on the outcome of patients treated for PMR in which concomitant rheumatic diseases contributing to symptoms are considered. Although mortality is not increased in PMR in comparison to ethnically matched populations (9, 10), relapses and recurrences are common (11). These events may lead to increased morbidity related to prolonged steroid therapy (12). Relapses have been often attributed to the speed of corticosteroid tapering (9, 10) or to a particular genetic background (13, 14) . Different alternative therapies have been proposed to facilitate steroid discontinuation (12). Among them MTX has proved to be effective (8) . MTX maintained its effi cacy over time because MTX-treated patients had less fl are-ups of PMR and lower indexes of infl ammation. However, no difference in the incidence of steroid-related side effects was found between MTX-treated patients and controls. Both the number of patients with side-effects and the mean number of side-effects were similar. The reliability of data obtained retrospectively from elderly patients (80% of cases) or their relatives (20%) could be questioned. In many instances, patients were accompanied to the clinic by relatives or care-givers who also helped to remember the clinical history. In addition, discussion with the patients' GPs and review of clinical charts helped to ascertain the major clinical events. The interviewers were unaware of the treatment choice. Underestimation of the incidence of side-effects and fl are-ups, although possible, should not have affected differently the two subgroups of patients. Serious complications of steroid treatment were rare in either groups. This could be due to the fact that, in general, patients enrolled in clinical trials are in average healthier than the remaining patients. This is true also for our study, where exclusion criteria included most conditions adversely affected by MTX or prednisone treatment, such as chronic hepatitis, liver cirrhosis, or serum aminotransferase levels of more than twice the normal value; chronic lung disease; poorly controlled diabetes mellitus (fasting plasma glucose >120 mg/dL); gastric or duodenal ulcer; osteoporotic fractures; peripheral neuropathy; epilepsy; renal failure; poorly controlled hypertension (blood pressure > 140/90 mm Hg); malabsorption; haemolytic or defi ciency anaemia; platelet count <150x10 9 /L; white blood cell count <3.5x10 9 /L; neutrophil count <1.5x10 9 / L; acute or chronic active infection; history of neoplasia; corticosteroid medication in the last month, previous therapy with MTX or with other immunosuppressive agents; or history of chronic alcohol abuse or drug addiction. Patients with many of these disorders, being at increased risk of steroid-related side effects, are those who could benefi t more from the addition of a steroid-sparing agent, such as MTX. To assess whether MTX supplementation therapy could spare some side-effects of steroids, a prospective evaluation of unselected patients is probably more appropriate. There were only few differences between patients treated with MTX and prednisone and those treated with prednisone alone (Table II) . In particular, the number of patients still on steroids, the mean cumulative dosage of steroids used, the number of patients with fl are-ups, the visual analogue scale evaluation of patient's pain and general health, the physician's opinion, the number of patients with arthritis and the mean HAQ value were not significantly different in the two groups. Giant cell arteritis occurred in 3/57 (5.3%) of patients during the follow-up. It is remarkable to observe that it did not occur in patients who were treated with MTX, although this difference was not statistically signifi cant. By summing up the fi gures of the controlled trial with those of the present follow-up, the cumulative dosage of steroid was 0.9 g lower in MTX-treated patients, but this difference did not reach statistical signifi cance. On the contrary, the number of fl are-ups remained signifi cantly lower in MTX-treated patients. However, due to the retrospective design of the present study, these results should be interpreted with caution. Almost half of the patients enrolled in the original therapeutic trial still showed musculoskeletal complaints fi ve years after completion. This fact is not surprising considering their mean age of nearly 80 years. As expected, most of them had OA, non-specifi c arthralgia, or fi bromyalgia. Two of them had an undifferentiated form of arthritis which could be interpreted as peripheral manifestation of PMR, two were still affected by PMR and 1 had developed rheumatoid arthritis. In many cases, the differential diagnosis between PMR and associated rheumatic complaint was diffi cult. Accordingly, a few patients could have been erroneously treated with steroids by their GPs for a condition that was not steroid-sensitive. In addition, 31.6% of patients assumed non-steroidal anti-infl ammatory-drugs or analgesics for their joint pain. The possibility of steroid-resistant PMR has been described, but its real occurrence is unknown. In our series of 57 patients enrolled in a clinical trial, 2 (3.5%) had persistent symptoms of PMR despite steroid treatment and 15 (26.3%) had to assume steroid to control symptoms of PMR approximately six years after treatment inception. The fact that one third of patients with PMR has to assume steroids for over six years is in contrast with the common belief that PMR is a benign, self-limiting condition. The fate of PMR patients not treated with steroids is probably not very different, with 32% still complaining of symptoms after a mean period of 7.1 years (15) . The percentage of patients needing long-lasting treatment ranged between 15.8% after a four-year follow-up in the study of Ayoub et al. (16) and 50.8% after a 5.5-year follow-up in the study of Delecouriere et al. (17) . With shorter follow-ups (less than two years), the percentage of patients needing continuous treatment was higher with fi gures comprised between 50.7 % and 97% (18, 19) . A remarkable exception was the result of Weyand et al. (20) , who showed only 1/27 (3.7%) patients still in need of steroids after a mean follow-up of 1.8 years. There is no convincing explanation for this variability since several characteristics of the different cohorts, such as male to female ratio, or the incidence of giant cell arteritis during follow-up, were similar in the different cohorts of patients. This fact may refl ect a higher propensity of European rheumatologists to prolong steroid treatment in order to prevent possible recurrences. An additional result of this study was the observation that patients who were cured from their PMR still show elevation of laboratory indexes of infl ammation. This could be due, at least in part, to the age-related increase of infl ammation that has been shown also in the healthy elderly (21) . MTX-treated patients had a tendency toward less infl ammatory residual disease activity over fi ve years, a fact that emphasizes the potential usefulness of this drug. In fact, they had slightly lower ESR and signifi cantly lower CRP than patients treated with steroids alone, who assumed a higher cumulative dosage of steroids. In conclusion, we have shown that the addition of MTX to conventional steroid treatment cannot decrease the incidence of steroid-related side effects in PMR patients, even in the long term. This could be surprising in view of the lower cumulative dosage of steroids that MTX-treated patients assumed, at least in the fi rst 76 weeks of treatment (8) . We feel that the controlled randomised trial is not the ideal setting to test the hypothesis that a steroid-sparing treatment is also side-effect-sparing, because a subset of relatively healthy patients is selected. An open randomised study of consecutive unselected patients could represent the best design to answer this question.
